Literature DB >> 3608455

CT evaluation of mediastinal masses.

M Rebner, B H Gross, J M Robertson, D R Pennes, D L Spizarny, G M Glazer.   

Abstract

CT is an important modality for imaging mediastinal masses, and certain CT attenuation features (fat, calcium, or water attenuation, contrast enhancement) are well known to suggest specific diagnoses. In a series of 132 consecutive patients with tissue-proven mediastinal masses, these specific CT features were present in only 16. We evaluated the ability of CT to differentiate soft tissue mediastinal masses based on morphology and distribution of disease. Metastatic disease and lymphoma accounted for 69% of masses in this series, and CT could not generally differentiate them. However, CT was helpful in differential diagnosis in certain settings. CT demonstration of multiple mediastinal masses when conventional radiographs showed a single mass generally excluded diagnoses such as thymoma and teratoma. CT demonstration of a single middle mediastinal mass, frequently missed by conventional radiography, made metastatic disease a much more likely diagnosis than lymphoma. Finally, CT demonstration of certain ancillary findings strongly favored a diagnosis of lymphoma (axillary adenopathy) or metastatic disease (solitary pulmonary mass, focal liver lesions, bone lesions).

Entities:  

Mesh:

Year:  1987        PMID: 3608455     DOI: 10.1016/0730-4862(87)90033-3

Source DB:  PubMed          Journal:  Comput Radiol        ISSN: 0730-4862


  3 in total

1.  Caval chemodectoma in a cat.

Authors:  Irene Martinez; Daniel Brockman; Katarzyna Purzycka
Journal:  JFMS Open Rep       Date:  2022-07-05

2.  PET imaging of primary mediastinal tumours.

Authors:  K Kubota; S Yamada; T Kondo; K Yamada; H Fukuda; T Fujiwara; M Ito; T Ido
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

3.  Long-term outcome of cats with acquired myasthenia gravis without evidence of a cranial mediastinal mass.

Authors:  Thomas Mignan; Laurent Garosi; Mike Targett; Mark Lowrie
Journal:  J Vet Intern Med       Date:  2019-11-20       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.